Micrologix completes Phase II enrollment

Micrologix Biotech (TSE:MBI; MGIXF) completed enrollment in its U.S. placebo-controlled, dose-ranging Phase II trial of MBI 594AN for the treatment of acne. Of the 75 enrolled patients, 55 have comple...